Interdisciplinary cooperation in the treatment of complex patients with advanced testicular germ cell tumor

被引:0
作者
Heidenreich, A
Krege, S
Flasshove, M
机构
[1] Univ Cologne, Klin & Poliklin Urol, Sekt Urol Onkol, D-50931 Cologne, Germany
[2] Univ Klinikum Essen, Innere Klin, Essen, Germany
[3] Univ Klinikum Essen, Klin & Poliklin Urol, Essen, Germany
来源
UROLOGE A | 2004年 / 43卷 / 12期
关键词
testis cancer; residual tumor resection; seminoma; nonseminoma; chemotherapy; retroperitoneal lymphadenectomy;
D O I
10.1007/s00120-004-0728-x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Testicular germ cell tumors represent the classic example of a curable solid cancer even in the metastatic stage. Cure rates are as high as 95% and 80-85% in patients with good and intermediate prognosis; even in patients with poor prognosis cure rates of 50% have been achieved by interdisciplinary collaboration of all specialties involved in the management of testis cancer. Standardization of diagnosis and therapy should be further optimized due to the recently published interdisciplinary national and European guidelines. Besides realization of standardized guidelines, treatment of patients with extensive primary disease or recurrent germ cell tumors following standard therapy requires comprehensive knowledge in conservative and surgical management, which is basically only available at specialized cancer centers. Patients with complex findings, especially if associated with a poor prognosis according to IGCCCG, should be referred to specialized tertiary referral centers at a very early stage, since the cure rates depend not only on the consideration of guidelines but also on the expertise of the attending oncologist and surgeon. When treating these patients, one has to consider that inadequately administered chemotherapy (dosage, length of cycles, number of cycles) cannot be compensated for by surgery and that inadequately performed retroperitoneal lymphadenectomy or tumor resection cannot be compensated for by chemotherapy. In any cass, suboptimal primary therapy will result in inferior cure rates and an unnecessarily increased mortality rate.
引用
收藏
页码:1521 / 1530
页数:10
相关论文
共 37 条
[1]   Prediction of necrosis after chemotherapy of advanced germ cell tumors: Results of a prospective multicenter trial of the German Testicular Cancer Study Group [J].
Albers, P ;
Weissbach, L ;
Krege, S ;
Kliesch, S ;
Hartmann, M ;
Heidenreich, A ;
Walz, P ;
Kuczyk, M ;
Fimmers, R .
JOURNAL OF UROLOGY, 2004, 171 (05) :1835-1838
[2]   Thoracoabdominal resection of retrocrural residual cancers [J].
Albers, P ;
Höltl, W ;
Heidenreich, A ;
Aharinejad, S .
AKTUELLE UROLOGIE, 2004, 35 (02) :141-150
[3]   Surgery in metastatic testicular cancer [J].
Albers, P ;
Melchior, D ;
Müller, SC .
EUROPEAN UROLOGY, 2003, 44 (02) :233-244
[4]   Testicular tumors.: Mortality and recurrence after inadequate therapy [J].
Albers, P ;
Dommer, K ;
Müller, SC .
UROLOGE-AUSGABE A, 1998, 37 (06) :625-628
[5]   The growing teratoma syndrome:: results of therapy and long-term follow-up of 33 patients [J].
André, F ;
Fizazi, K ;
Culine, S ;
Droz, JP ;
Taupin, P ;
Lhommé, C ;
Terrier-Lacombe, MJ ;
Théodore, C .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (11) :1389-1394
[6]   High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis [J].
Beyer, J ;
Stenning, S ;
Gerl, A ;
Fossa, S ;
Siegert, W .
ANNALS OF ONCOLOGY, 2002, 13 (04) :599-605
[7]   First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis [J].
Bokemeyer, C ;
Kollmannsberger, C ;
Meisner, C ;
Harstrick, A ;
Beyer, J ;
Metzner, B ;
Hartmann, JT ;
Schmoll, HL ;
Einhorn, L ;
Kanz, L ;
Nichols, C .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3450-3456
[8]   21-DAY CYCLES OF ORAL ETOPOSIDE IN HEAVILY PRETREATED METASTATIC GERM-CELL CANCER [J].
CANTWELL, BMJ ;
MILLWARD, MJ ;
LIND, MJ ;
CALVERT, AH .
LANCET, 1990, 336 (8721) :1011-1011
[9]   Treatment of early stage testicular seminoma [J].
Classen, J ;
Souchon, R ;
Hehr, T ;
Bamberg, M .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (08) :475-481
[10]   Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma [J].
Collette, L ;
Sylvester, RJ ;
Stenning, SP ;
Fossa, SD ;
Mead, GM ;
de Wit, R ;
de Mulder, PHM ;
Neymark, N ;
Lallemand, E ;
Kaye, SB .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (10) :839-846